Reimagining Cardiovascular Prevention in the Critical Decades

Overview

Cardiovascular disease often begins long before symptoms appear. The PRIME-Heart Initiative is a bold, forward-thinking effort focused on early identification and prevention during the critical decades of adulthood (ages 25 to 65) when modifiable risk factors often emerge.

PRIME-Heart seeks to redefine prevention by shifting cardiovascular care from short-term risk prediction to a lifetime benefit approach through a three-part strategy:

• Earlier risk detection
• Sequenced, risk-guided interventions
• Clinical translation and integration

Our Process

Each focus area begins with a Roundtable that brings together leading experts to shape priorities and insights. These discussions inform the development of clinician- and patient-facing materials, with each phase building on the last.

A dedicated patient forum will ensure that lived experiences and perspectives guide every phase of the initiative.

The PRIME-Heart Initiative is supported by:
Amgen, AstraZeneca, Boehringer Ingelheim, HeartFlow, Novartis, Novo Nordisk